Key points are not available for this paper at this time.
Interview with Dr. Alice Shaw on a new model for accelerating the development of promising oncology drugs. (10:06)Download Increasingly, firms developing cancer drugs are forgoing standard phased development for a seamless approach of adding cohorts to a first-in-human trial to study doses and activity in various cancers. Key regulatory interactions and protections may therefore be missing.
Prowell et al. (Wed,) studied this question.